EMAIL THIS PAGE TO A FRIEND

Sexually transmitted infections

Molecular epidemiology of Neisseria gonorrhoeae isolates from Saskatchewan, Canada: utility of NG-MAST in predicting antimicrobial susceptibility regionally.


PMID 24503900

Abstract

To investigate the molecular epidemiology of isolates of Neisseria gonorrhoeae from Saskatchewan, Canada, using Neisseria gonorrhoeae multi antigen sequence typing (NG-MAST), and to assess associations between antimicrobial susceptibility (AMS) and specific strain types (STs). 320 consecutive gonococcal isolates, collected between 2003 and 2008, were typed by NG-MAST. STs were grouped if one of their alleles was common and the other differed by ≤1% in DNA sequence. AMS was determined by agar dilution (CLSI) to seven antibiotics. N gonorrhoeae isolates were resolved into 82 individual NG-MAST STs and 18 NG-MAST ST groups with groups 25, 3655, 921, 3654, 3657 and 3656 comprising 53.4% (171/320) of the isolates. N gonorrhoeae isolates susceptible to all the tested antimicrobials were significantly (p<0.05) associated with ST 25 (87%). Other significant associations between ST and AMS included: ST 3654 and isolates with minimum inhibitory concentrations of ≥0.03 mg/L to third generation cephalosporins; ST 3711 (100%) and TRNG; and ST/group 3654 (43%) and chromosomal resistance to penicillin and tetracycline. Several NG-MAST STs/groups were significantly associated with isolates with chromosomal resistance to tetracycline. Isolates resistant to ciprofloxacin (n=5) and azithromycin (n=2) appeared as individual STs. Significant associations were observed among individual STs, sex and age of the patient, and regional and temporal distributions. Associations between N gonorrhoeae AMS and NG-MAST STs were identified and may be useful in predicting AMS regionally. Because STs in different countries vary considerably, the use of NG-MAST for the prediction of AMS globally requires further study.

Related Materials

Product #

Image

Description

Molecular Formula

Add to Cart

PHR1088
Azithromycin, Pharmaceutical Secondary Standard; Certified Reference Material
C38H72N2O12 · 2H2O
C5793
Ceftriaxone disodium salt hemi(heptahydrate), third-generation cephalosporin antibiotic
C18H16N8Na2O7S3 · 3.5H2O
89434
Ceftriaxone disodium salt hemi(heptahydrate), analytical standard
C18H16N8Na2O7S3 · 3.5H2O
C0691000
Ceftriaxone sodium, European Pharmacopoeia (EP) Reference Standard
C18H16N8Na2O7S3 · 3.5H2O
1098184
Ceftriaxone sodium, United States Pharmacopeia (USP) Reference Standard
C18H16N8Na2O7S3 · 3.5H2O
PHR1382
Ceftriaxone Sodium, Pharmaceutical Secondary Standard; Certified Reference Material
C18H16N8Na2O7S3 · 3.5H2O
1134335
Ciprofloxacin hydrochloride, United States Pharmacopeia (USP) Reference Standard
C17H18FN3O3 · HCl · H2O
S9007
Spectinomycin dihydrochloride pentahydrate, potency: ≥603 μg per mg
C14H24N2O7 · 2HCl · 5H2O
S4014
Spectinomycin dihydrochloride pentahydrate, powder, BioReagent, suitable for cell culture
C14H24N2O7 · 2HCl · 5H2O
46738
Spectinomycin dihydrochloride pentahydrate, VETRANAL, analytical standard
C14H24N2O7 · 2HCl · 5H2O
S2647
Spectinomycin dihydrochloride pentahydrate, powder, γ-irradiated
C14H24N2O7 · 2HCl · 5H2O
1618003
Spectinomycin hydrochloride, United States Pharmacopeia (USP) Reference Standard
C14H24N2O7 · 2HCl · 5H2O
T0600000
Tetracycline hydrochloride, European Pharmacopoeia (EP) Reference Standard
C22H24N2O8 · HCl